iambic-therapeutics
Develops novel medicines using an AI-driven discovery platform.
Company facts
- Founded
- 2019
- Employees
- 133
- Headquarters
- United States
- CEO
- Tom Miller
- Type
- Private
- Funding
- Series C · $103M · 2025
About
Optimized medicines for optimized profiles. Our physics-based AI algorithms drive a high-throughput experimental platform, converting new molecular designs to new biological insights each week. Exploring multiple profiles in parallel ensures that we design molecules to solve the right problems in disease biology. Our AI-driven platform deeply explores chemical space, revealing novel mechanisms of action and delivering diverse high-quality leads. We deliver accurate and data-efficient physics-based AI technologies that span from early-stage discovery to the clinic. Through AI-driven, high-throughput experimentation, we transition from new molecular designs to new biological data each week. We have a proprietary pipeline of differentiated clinical candidates delivered at a pace years faster than the industry standard. Our platform-driven pipeline includes first-in-class and best-in-class programs, and we are unlocking the untapped potential of known targets while transforming seemingly undruggable targets into breakthrough treatment opportunities.